Prelude Capital Management’s Gain Therapeutics GANX Stock Holding History

Prelude Capital Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.7K	Hold	35,820	–	–	0.01%	1147
2026 Q1	$69.5K	Hold	35,820	–	–	0.01%	1096
2025 Q4	$115K	Hold	35,820	–	–	0.01%	1165
2025 Q3	$63.4K	Hold	35,820	–	–	﹤0.01%	1094
2025 Q2	$64.5K	Hold	35,820	–	–	0.01%	949
2025 Q1	$68.4K	Hold	35,820	–	–	0.01%	1074
2024 Q4	$77.4K	Hold	35,820	–	–	﹤0.01%	1119
2024 Q3	$63.8K	Hold	35,820	–	–	﹤0.01%	1196
2024 Q2	$45.9K	Hold	35,820	–	–	﹤0.01%	1151
2024 Q1	$135K	Sell	35,820 -22,280	-38%	-$92.4K	0.01%	1171
2023 Q4	$190K	Hold	58,100	–	–	0.01%	954
2023 Q3	$191K	Hold	58,100	–	–	0.01%	915
2023 Q2	$260K	Hold	58,100	–	–	0.02%	712
2023 Q1	$280K	Hold	58,100	–	–	0.02%	674
2022 Q4	$182K	Hold	58,100	–	–	0.01%	992
2022 Q3	$189K	Hold	58,100	–	–	0.01%	1088
2022 Q2	$209K	Hold	58,100	–	–	0.01%	1270
2022 Q1	$238K	Hold	58,100	–	–	0.01%	1182
2021 Q4	$315K	Hold	58,100	–	–	0.01%	1287
2021 Q3	$433K	Hold	58,100	–	–	0.01%	964
2021 Q2	$581K	Hold	58,100	–	–	0.02%	868
2021 Q1	$867K	Buy	+58,100	New	+$763K	0.02%	653

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Prelude Capital Management's GANX Position: Q2 2026 in Review

Prelude Capital Management held its Gain Therapeutics (GANX) position steady in Q2 2026 at 35,820 shares worth $72.7K. The position accounts for 0.01% of the portfolio, ranked #1147.

Prelude Capital Management first reported a position in GANX in Q1 2021 and has held it in 22 quarters since. The position peaked at $867K in Q1 2021. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Prelude Capital Management held 35,820 shares of Gain Therapeutics worth $72.7K as of Q2 2026.
Prelude Capital Management left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1147 holding.
Prelude Capital Management first reported a position in Gain Therapeutics in Q1 2021 and has held it in 22 quarters since.
Prelude Capital Management's Gain Therapeutics position peaked at $867K in Q1 2021.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.